Phase III trials begin: In October, Adimmune initiated its Quadrivalent Influenza Vaccine Phase III trial in Europe. The recruitment of participants is going well with over 1,000 participants enrolled in the program. It is expected that the recruitment process will be completed by the end of 2016. Adimmune will begin the process for a Biologics License Application (BLA) in 2017. This is the largest clinical trial in Europe initiated by a Taiwanese vaccine company, and a milestone for Adimmune to begin selling its own-brand product in Europe.
About Adimmune: Adimmune is the No.1 flu vaccine provider in Asia to obtain US, EU, China and Taiwan cGMP, and will obtain Japan cGMP in 2017. The Company has ample capacity in flu vaccine of 25mn doses/year and pre-filled syringe (PFS) of 25mn doses/year. Its solid capability in high-quality commercial scale human vaccine manufacturing has enabled Adimmune to expand its business to China, Europe, Japan and the US. Currently Adimmune is the largest provider of flu vaccine (3 strains) and sole provider of Japanese Encephalitis vaccine and Tetanus vaccine in Taiwan. Adimmune is listed on the Taiwan Stock Exchange (4142 TT).
For more information, please visit http://www.adimmune.com.tw
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/adimmune-begins-shipments-to-eu-and-phase-iii-trial-in-europe-300367987.html